Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.64 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.64 |
| ▸ | PIK3CD | O00329 | 16/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.59 |
| ▸ | NNMT | P40261 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182805 | 0.85 | PIK3CD (0.58) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 | |
| SCHEMBL182495 | 0.85 | PIK3CA (0.58) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 | |
| SCHEMBL183174 | 0.84 | PIK3CA (0.57) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 | |
| SCHEMBL183097 | 0.83 | MKNK1 (0.61) | MKNK1MKNK2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL182718 | 0.83 | PIK3CD (0.61) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 | |
| SCHEMBL182740 | 0.83 | MAP4K4 (0.56) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 | |
| SCHEMBL182555 | 0.82 | MKNK1 (0.66) | MKNK1MKNK2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL182536 | 0.81 | PIK3CA (0.60) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 | |
| SCHEMBL14880381 | 0.81 | PIK3CD (0.72) | MKNK1MKNK2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL14880326 | 0.81 | PIK3CD (0.72) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049502-B1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | claimed |
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | NOVARTIS AG | 2009-10-15 | — | — | US | claimed |
| EP-2049502-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2009-04-22 | — | — | EP | claimed |
| WO-2008012326-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-31 | — | — | WO | claimed |
| EP-2049502-B1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIK3CA | MKNK1 153/4885MKNK2 136/4885PIK3CD 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.